Purdue Pharmaceuticals, L.P.
Headquarters
One Stamford Forum
Stamford
Connecticut
06901-3431
United States
Tel: 203-588-8000
Fax: 203-588-8850
Website: http://www.purduepharma.com/
About Purdue Pharmaceuticals, L.P.
Purdue Pharmaceuticals, L.P., headquartered in Stamford, CT, is a privately held pharmaceutical company founded by physicians and focused on meeting the needs of healthcare providers and the patients in their care. Together with its independent associated companies, Purdue is dedicated to finding, developing, and bringing to market new medicines and related products that improve health outcomes. The company has long been known for its pioneering research on persistent pain, a principal cause of human suffering.
Purdue also has a growing line of non-prescription products including laxatives, microbicides, and nutraceuticals. The company is dedicated to serving the evolving needs of healthcare providers, patients, and caregivers with prescription and non-prescription medicines. A commitment to innovation and caring spans every aspect of the organization, from discovering and launching new medicines to demonstrating their medical value.
Purdue has led the battle against inadequate treatment of pain by developing sustained-release medications to manage pain. Its sales, marketing, and medical education professionals provide the healthcare community with comprehensive educational materials and programs relating to pain management.
In 1993, Purdue established Partners Against Pain® as a resource to help patients, caregivers, and healthcare professionals advance standards of pain care and alleviate unnecessary suffering through education and advocacy. Purdue has also assumed a leading role in addressing the serious public health problem of prescription drug abuse, supporting programs intended to help stem abuse.
At its research facilities in Cranbury, New Jersey, Purdue scientists are discovering new compounds to treat pain and developing formulations and delivery systems to help improve patient safety.
196 articles with Purdue Pharmaceuticals, L.P.
-
Following Purdue Pharma’s Chapter 11 filing last month, other opioid makers are exploring ways to settle their own litigation problems by participating in the OxyContin drugmaker’s bankruptcy proceedings.
-
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
-
Days after reaching a tentative agreement with a majority of states involved in litigation against the company over its role in the opioid crisis in the United States, Purdue Pharmaceuticals filed Chapter 11 bankruptcy.
-
Fears Nachawati Opioid Litigation Trial Lawyers Encouraged by Purdue Pharma Settlement Talks
9/12/2019
Meaningful settlement negotiations by Big Pharma could result in more rapid relief for distressed communities
-
Purdue Pharmaceuticals has reached a tentative settlement in thousands of opioid cases that could cost the company about $12 billion, but some litigation against the firm is expected to continue over its role in the opioid crisis.
-
Purdue Pharma may file for bankruptcy this week after negotiations over a multi-billion opioid claims settlement have stalled, multiple sources are reporting.
-
Citing unnamed sources “familiar with the matter,” Reuters said that the company will have no choice but to file for bankruptcy should a settlement not be agreed upon.
-
The Prescription Drug Safety Network Significantly Expands Its Reach in Year 2 and Reports an Average 48% Knowledge Gain Nationwide
8/20/2019
Purdue announces expanded support for the Prescription Drug Safety course through an additional sponsorship in Tennessee
-
Novo Nordisk intends to use the site to support manufacturing of its oral type 2 diabetes treatment that is under review for approval by the U.S. Food and Drug Administration.
-
Recovery Activists and Parents to Join Together in Boston at Second Major Purdue Pharma Court Hearing
7/29/2019
Massachusetts Superior Court will address the merits of the complaints filed against Purdue Pharma by Attorney General Maura Healy which Purdue is attempting to have dismissed.
-
The Sackler family has earned billions from the sale of OxyContin and the backlash against the family has increased in-fighting, according to reports.
-
Adlon Therapeutics L.P. Joins the Prescription Drug Safety Network
7/9/2019
National public-private coalition supports education around safe and responsible prescription medication use through digital education programs created by EVERFI
-
BioSpace Movers and Shakers: July 3
7/3/2019
Biotech and pharma companies strengthen their executive leadership and board positions. -
Julie Ducharme, BPharm, MSc, PhD Named Vice President and Chief Scientific Officer of Purdue Pharma L.P.
7/2/2019
She will report directly to President and CEO Craig Landau, MD.
-
During the first presidential debate of Democratic candidates vying for that party’s presidential nomination, it didn’t take long for the pharma industry to take center stage.
-
Imbrium Therapeutics Advances Insomnia Pipeline Through Initiation of a Phase 2 Study of Potential First-in-Class Molecule for Insomnia Associated with Alcohol Cessation
6/25/2019
Latest research on drug safety supports continued development of novel small molecule, IMB-115
-
In a statement, WHO said it was discontinuing two guidelines that have been in place since 2011 and 2012 “in light of new scientific evidence that has emerged since the time of their publication” regarding the dangers of opioid abuse.
-
Purdue, Bristol-Myers Squibb and Apotex have been singled out in opioid-related lawsuits in Canada.
-
Adlon Therapeutics L.P. to Provide Funding Opportunities for Research to Expand Understanding of ADHD
5/13/2019
Company accepting proposals for investigator-initiated research to evaluate outcomes associated with certain assessments of ADHD, and explore the burden and impact of ADHD on adolescent and adult patients
-
Eisai and Purdue Pharma Announce Buy Out of Purdue's Rights in Worldwide Collaboration to Develop and Commercialize Lemborexant
5/1/2019
Eisai Inc. and Purdue Pharma L.P. announced that Eisai will buy out Purdue's rights to the worldwide collaboration for the development and commercialization of lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multiple sleep-wake disorders, including insomnia and irregular sleep-wake rhythm disorder (ISWRD) in patients with Alzheimer's Disease.